NCT02201524

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

A Phase 2, Randomized, Double-blind, Placebo-controlled Study To Evaluate Safety And Efficacy Of Pf-04965842 In Subjects With Moderate To Severe Psoriasis

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in patients with moderate to severe psoriasis. The study will include three PF-04965842 groups (200 mg daily, 400 mg daily and 200 mg twice daily) and a placebo group. The treatment period will be 4 weeks in duration and will be followed up by a 4 week follow up period.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	PF-04965842	Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks
DRUG	PF-04965842	Subjects will receive 400 mg PF 04965842 daily for 4 weeks
DRUG	PF-04965842	Subjects will receive 200 mg PF 04965842 daily for 4 weeks
OTHER	Placebo	Subjects will receive placebo for 4 weeks

Timeline

• Start date: 2014-11-01
• Primary completion: 2015-09-01
• Completion: 2015-09-01
• First posted: 2014-07-28
• Last updated: 2016-10-05
• Results posted: 2016-10-05

Locations

45 sites across 2 countries: United States, Canada